{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:59:41Z","timestamp":1785110381442,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Telemedicine-Assisted Buprenorphine Induction (TABI) is a hybrid treatment model combining in-person initiation with remote follow-up, developed to improve access to opioid agonist maintenance treatment (OAMT) in India. While clinical trials demonstrated its non-inferiority to standard care, process evaluations are essential to understand contextual factors influencing its implementation and sustainability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A qualitative process evaluation, guided by the RE-AIM framework, was conducted alongside a randomized controlled trial comparing TABI with in-person induction. Fourteen patients with opioid use disorder (OUD) who underwent TABI in the previous three months and four TABI providers were interviewed using semi-structured guides. Thematic analysis was conducted iteratively, and data saturation was confirmed at the 14th patient interview. Data were analyzed using the framework method, combining deductive coding based on RE-AIM domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TABI improved treatment reach by reducing travel and time barriers, although digital literacy challenges, network instability, and providers\u2019 bias for judging clinical suitability might constrain implementation. Participants reported positive outcomes, including reduced opioid use and functional improvements. Adoption was supported by family engagement and provider trust but hindered by stigma and technological barriers. Implementation fidelity was largely maintained, with providers adapting workflows to address connectivity disruptions. Sustainability was linked to structured follow-up, hybrid care reinforcement, and motivational interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TABI is an acceptable, feasible, and effective model for OAMT delivery in low-resource settings. Future scale-up should address digital inequities, strengthen psychosocial and motivational supports, embed periodic in-person reinforcement, and integrate stigma-reduction strategies to optimize long-term treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00670-6","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:23:32Z","timestamp":1779798212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From access to sustainability: understanding telemedicine-based buprenorphine induction through a RE-AIM lens"],"prefix":"10.1186","volume":"21","author":[{"given":"Abhishek","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet Singh","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessy B.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashish","family":"Ranchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragyapti","family":"Malav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini S.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. N.","family":"Subodh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"10208","key":"670_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379.","journal-title":"Lancet"},{"key":"670_CR2","unstructured":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization; 2009. https:\/\/www.who.int\/publications\/i\/item\/9789241547543."},{"key":"670_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2471\/BLT.12.111815","volume":"91","author":"R Rao","year":"2013","unstructured":"Rao R, Agrawal A, Kishore K, Ambekar A. Delivery models of opioid agonist maintenance treatment in South Asia: a good beginning. Bull World Health Organ. 2013;91:150\u20133.","journal-title":"Bull World Health Organ"},{"issue":"12","key":"670_CR4","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1111\/add.15087","volume":"115","author":"H Jin","year":"2020","unstructured":"Jin H, Marshall BDL, Degenhardt L, Strang J, Hickman M, Fiellin DA, et al. Global opioid agonist treatment: a review of clinical practices by country. Addiction. 2020;115(12):2243\u201354.","journal-title":"Addiction"},{"issue":"1","key":"670_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/psychiatry.IndianJPsychiatry_14_17","volume":"59","author":"A Ambekar","year":"2017","unstructured":"Ambekar A, Murthy P, Basu D, Rao GP, Mohan A. Challenges in the scale-up of opioid substitution treatment in India. Indian J Psychiatry. 2017;59(1):6\u20139.","journal-title":"Indian J Psychiatry"},{"key":"670_CR6","doi-asserted-by":"crossref","unstructured":"Power N, Archambault L, Perreault M. New challenges and opportunities for opioid agonist treatment access and retention: a scoping review. J Drug Issues. 2024:00220426241269828.","DOI":"10.1177\/00220426241269828"},{"issue":"1","key":"670_CR7","doi-asserted-by":"publisher","first-page":"e2252381","DOI":"10.1001\/jamanetworkopen.2022.52381","volume":"6","author":"R Hailu","year":"2023","unstructured":"Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML. Telemedicine use and quality of opioid use disorder treatment in the US during the COVID-19 pandemic. JAMA Netw Open. 2023;6(1):e2252381\u20132252381.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"670_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S2215-0366(22)00374-1","volume":"10","author":"JTW Teck","year":"2023","unstructured":"Teck JTW, Zlatkute G, Perez A, Dritschel H, Ghosh A, Potenza MN, et al. Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory. Lancet Psychiatry. 2023;10(1):50\u201364.","journal-title":"Lancet Psychiatry"},{"key":"670_CR9","volume-title":"Telemedicine Practice Guidelines: Enabling Registered Medical Practitioners to Provide Healthcare Using Telemedicine","author":"Board of Governors in supersession of Medical Council of India; NITI Aayog","year":"2020","unstructured":"Board of Governors in supersession of Medical Council of India; NITI Aayog. Telemedicine Practice Guidelines: Enabling Registered Medical Practitioners to Provide Healthcare Using Telemedicine. New Delhi: Ministry of Health & Family Welfare, Government of India; 2020."},{"key":"670_CR10","unstructured":"Dhillon HS, Ghosh A. Telemedicine-assisted buprenorphine induction versus standard of care: a randomized controlled, non-inferiority trial. 2023."},{"issue":"10","key":"670_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_432_24","volume":"66","author":"A Ghosh","year":"2024","unstructured":"Ghosh A, Kale A, Laxmi R, Naik SS, Subodh BN, Basu D. Breaking barriers: Assessing the feasibility and acceptability of telemedicine-assisted buprenorphine induction for opioid use disorder in India. Indian J Psychiatry. 2024;66(10):956\u201362.","journal-title":"Indian J Psychiatry"},{"key":"670_CR12","doi-asserted-by":"crossref","unstructured":"Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: medical research council guidance. BMJ. 2015;350.","DOI":"10.1136\/bmj.h1258"},{"issue":"9","key":"670_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322\u20137.","journal-title":"Am J Public Health"},{"issue":"1","key":"670_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field methods. 2006;18(1):59\u201382.","journal-title":"Field methods"},{"key":"670_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:1\u20138.","journal-title":"BMC Med Res Methodol"},{"issue":"23","key":"670_CR16","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1001\/jama.2020.21512","volume":"324","author":"HA Huskamp","year":"2020","unstructured":"Huskamp HA, Busch AB, Uscher-Pines L, Barnett ML, Riedel L, Mehrotra A. Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic. JAMA. 2020;324(23):2440\u20132.","journal-title":"JAMA"},{"issue":"1","key":"670_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/JAN.0000000000000426","volume":"34","author":"M Onderdonk","year":"2023","unstructured":"Onderdonk M, Goldstein N. Substance use disorder treatment through telemedicine in the age of COVID-19. J Addict Nurs. 2023;34(1):96\u20137.","journal-title":"J Addict Nurs"},{"issue":"12","key":"670_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamapsychiatry.2020.1698","volume":"77","author":"LA Lin","year":"2020","unstructured":"Lin LA, Fernandez AC, Bonar EE. Telehealth for substance-using populations in the age of coronavirus disease 2019: recommendations to enhance adoption. JAMA psychiatry. 2020;77(12):1209\u201310.","journal-title":"JAMA psychiatry"},{"issue":"9","key":"670_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11920-022-01346-z","volume":"24","author":"H Mahmoud","year":"2022","unstructured":"Mahmoud H, Naal H, Whaibeh E, Smith A. Telehealth-based delivery of medication-assisted treatment for opioid use disorder: a critical review of recent developments. Curr Psychiatry Rep. 2022;24(9):375\u201386.","journal-title":"Curr Psychiatry Rep"},{"issue":"8","key":"670_CR20","doi-asserted-by":"publisher","first-page":"e2118487","DOI":"10.1001\/jamanetworkopen.2021.18487","volume":"4","author":"E Weintraub","year":"2021","unstructured":"Weintraub E, Seneviratne C, Anane J, Coble K, Magidson J, Kattakuzhy S, et al. Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. JAMA Netw Open. 2021;4(8):e2118487\u20132118487.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"670_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2020.3940","volume":"324","author":"L Uscher-Pines","year":"2020","unstructured":"Uscher-Pines L, Huskamp HA, Mehrotra A. Treating patients with opioid use disorder in their homes: an emerging treatment model. JAMA. 2020;324(1):39\u201340.","journal-title":"JAMA"},{"issue":"14","key":"670_CR22","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use \\& Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use \\& Misuse"},{"issue":"1","key":"670_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12954-024-01043-5","volume":"21","author":"JV Couch","year":"2024","unstructured":"Couch JV, Whitcomb M, Buchheit BM, Dorr DA, Malinoski DJ, Korthuis PT, et al. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis. Harm Reduct J. 2024;21(1):125.","journal-title":"Harm Reduct J"},{"key":"670_CR24","doi-asserted-by":"publisher","first-page":"108646","DOI":"10.1016\/j.jsat.2021.108646","volume":"135","author":"T Marshall","year":"2022","unstructured":"Marshall T, Hancock M, Kinnard EN, Olson K, Abba-Aji A, Rittenbach K, et al. Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review. J Subst Abuse Treat. 2022;135:108646.","journal-title":"J Subst Abuse Treat"},{"key":"670_CR25","doi-asserted-by":"publisher","first-page":"209194","DOI":"10.1016\/j.josat.2023.209194","volume":"156","author":"AJ Ober","year":"2024","unstructured":"Ober AJ, Dopp AR, Clingan SE, Curtis ME, Lin C, Calhoun S, et al. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics. J Subst use Addict Treat. 2024;156:209194.","journal-title":"J Subst use Addict Treat"},{"key":"670_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-020-0253-y","volume":"15","author":"K Marchand","year":"2020","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15:1\u20139.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"670_CR27","doi-asserted-by":"crossref","unstructured":"Magill M, Martino S, Wampold BE. Defining the therapeutic relationship in the contexused in content analysis reviewt of alcohol use, other drug use, and behavior change: Principles and practices. J Subst Use Addict Treat. 2024:209398.","DOI":"10.1016\/j.josat.2024.209398"},{"key":"670_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-019-3995-y","volume":"21","author":"BB Dennis","year":"2020","unstructured":"Dennis BB, Sanger N, Bawor M, Naji L, Plater C, Worster A, et al. A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder. Trials. 2020;21:1\u201316.","journal-title":"Trials"},{"issue":"9","key":"670_CR29","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1111\/add.15875","volume":"117","author":"NS Karnik","year":"2022","unstructured":"Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, et al. The opioid use disorder core outcomes set (OUD\u2013COS) for treatment research: findings from a Delphi consensus study. Addiction. 2022;117(9):2438\u201347.","journal-title":"Addiction"},{"key":"670_CR30","unstructured":"Wiessing L, Akartuna D, Antoine J, Banka-Cullen P, Barbaglia MG, Belackova V, et al. The OPTIMUS international consensus guidance for monitoring user-reported outcomes of opioid maintenance treatment: a Delphi study. Int J Ment Health Addict. 2025:1\u201323."},{"key":"670_CR31","doi-asserted-by":"crossref","unstructured":"Aronowitz SV, Zucker N, Thompson M, James R, Clapp J, Mandell D. Patient and provider experiences with opioid use disorder care delivered via telehealth: a systematic mixed-studies review. Drug Alcohol Depend. 2024:112522.","DOI":"10.1016\/j.drugalcdep.2024.112522"},{"issue":"6","key":"670_CR32","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/ADM.0000000000001006","volume":"16","author":"JL Sousa","year":"2022","unstructured":"Sousa JL, Raja P, Huskamp HA, Mehrotra A, Busch AB, Barnett ML, et al. Perspectives of patients receiving telemedicine services for opioid use disorder treatment: A qualitative analysis of user experiences. J Addict Med. 2022;16(6):702\u20138.","journal-title":"J Addict Med"},{"key":"670_CR33","doi-asserted-by":"publisher","first-page":"111118","DOI":"10.1016\/j.drugalcdep.2024.111118","volume":"256","author":"B Burke","year":"2024","unstructured":"Burke B, Miller E, Clear B, Weiner SG. A qualitative study to determine perspectives of clinicians providing telehealth opioid use disorder treatment. Drug Alcohol Depend. 2024;256:111118.","journal-title":"Drug Alcohol Depend"},{"key":"670_CR34","doi-asserted-by":"publisher","first-page":"108999","DOI":"10.1016\/j.drugalcdep.2021.108999","volume":"228","author":"L Riedel","year":"2021","unstructured":"Riedel L, Uscher-Pines L, Mehrotra A, Busch AB, Barnett ML, Raja P, et al. Use of telemedicine for opioid use disorder treatment\u2013Perceptions and experiences of opioid use disorder clinicians. Drug Alcohol Depend. 2021;228:108999.","journal-title":"Drug Alcohol Depend"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00670-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00670-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00670-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:37:27Z","timestamp":1785109047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00670-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00670-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}